PolyPeptide Laboratories Announces Plans to Expand GMP Manufacturing Facilities
16 August 2005
In response to growing demand for therapeutic peptides, PolyPeptide Laboratories has announced plans to substantially increase its manufacturing capabilities in both the US and Europe.
The expansion will take place at two of PolyPeptide Laboratories' GMP manufacturing facilities: Torrance, CA and Malmo, Sweden. The result will be a doubling of the manufacturing capacity in Torrance and substantial increases in the capacity in Malmo.
The expansion plans for both facilities focus mainly on increased capacity for solid-phase peptide manufacturing. The increase in solid-phase capacity in the Torrance and Malmo facilities serves to complement the large solution-phase synthesis capabilities already present at the PolyPeptide Laboratories facilities in Malmo, Sweden and Hillerod, Denmark.
The decision to expand the facilities in response to the increasing demand from both biotech and pharmaceutical customers for experienced large-scale GMP peptide manufacturing will help to maintain PolyPeptide Laboratories' leading position in this exciting market. The combination of technical know-how, state-of-the-art production facilities and comprehensive regulatory support that PolyPeptide laboratories provides their customers is considered a critical advantage in the competitive drug development arena, and has helped to sustain double digit growth rates for the company. Both biotech and large pharmaceutical companies have benefited greatly from the experience and knowledge of PolyPeptide Laboratories in the development of their clinical peptide therapeutic compounds.
The new facilities are planned to begin production in 2006.
